Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy, Biologic therapy.

Institut Gustave Roussy, University of Paris Sud, Villejuif, France.

Survival: monthsCountry:France
Toxiciy Grade:5City/State/Province:Villejuif
Treatments:Chemotherapy, Biologic therapyHospital:Institut Gustave Roussy, University of Paris Sud
Drugs:Journal:Link
Date:Apr 2013

Description:

Patients:
This phase 3 study involved metastatic castration-resistant prostate cancer patients who were divided into two separate treatment groups. Group A consisted of 524 male patients with a median age of 68 years. Group B had 528 male patients with a median age of 68 years.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel and the biologic therapy agent zibotentan, which is an inhibitor of the endothelin A receptor and interferes with cancer progression.

Patients in group B were treated with docetaxel and a placebo.

Toxicities:
There were two treatment-related deaths due to heart failure in group A. Grade 1-2 alopecia and grade 3-4 peripheral swelling was also reported.

There was one treatment-related death in group B that was due to heart failure. Grade 3-4 neutropenia and leukopenia were also reported.

Results:
The median overall survival for groups A and B was 20.0 and 19.2 months, respectively.

Support:
This study was supported by AstraZeneca.

Correspondence: Dr. Karim Fizazi; email: [email protected]



Back